Literature DB >> 367597

Maytansine.

B F Issell, S T Crooke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 367597     DOI： 10.1016/s0305-7372(78)80014-0

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  27 in total

1.  Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.

Authors:  Simona Lapusan; Maria B Vidriales; Xavier Thomas; Stephane de Botton; Anne Vekhoff; Ruoping Tang; Charles Dumontet; Rodica Morariu-Zamfir; John M Lambert; Marie-Laure Ozoux; Philippe Poncelet; Jesus F San Miguel; Ollivier Legrand; Daniel J DeAngelo; Francis J Giles; Jean-Pierre Marie
Journal:  Invest New Drugs       Date:  2011-04-26       Impact factor: 3.850

Review 2.  Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.

Authors:  Noam Pondé; Philippe Aftimos; Martine Piccart
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

Review 3.  Strategies and challenges for the next generation of antibody-drug conjugates.

Authors:  Alain Beck; Liliane Goetsch; Charles Dumontet; Nathalie Corvaïa
Journal:  Nat Rev Drug Discov       Date:  2017-03-17       Impact factor: 84.694

Review 4.  Antibody-DM1 conjugates as cancer therapeutics.

Authors:  Manu Lopus
Journal:  Cancer Lett       Date:  2011-04-09       Impact factor: 8.679

5.  Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer.

Authors:  Alicia F C Okines; David Cunningham
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409

Review 6.  ADME of antibody-maytansinoid conjugates.

Authors:  Hans K Erickson; John M Lambert
Journal:  AAPS J       Date:  2012-08-09       Impact factor: 4.009

7.  Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.

Authors:  Andrew C Wood; John M Maris; Richard Gorlick; E Anders Kolb; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Raushan T Kurmasheva; Kathleen Whiteman; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-06-24       Impact factor: 3.167

Review 8.  The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.

Authors:  Véronique Diéras; Thomas Bachelot
Journal:  Target Oncol       Date:  2013-07-14       Impact factor: 4.493

Review 9.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

10.  P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.

Authors:  Ruoping Tang; Simy Cohen; Jean-Yves Perrot; Anne-Marie Faussat; Claudia Zuany-Amorim; Zora Marjanovic; Hamid Morjani; Fanny Fava; Elise Corre; Ollivier Legrand; Jean-Pierre Marie
Journal:  BMC Cancer       Date:  2009-06-23       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.